Sequella Home Page

Quick Facts

Someone in the world is newly infected with tuberculosis every second.

Our Strategy

Our strategy is to leverage our experience in handling highly hazardous microorganisms, our expertise in therapeutic development, our >150,000 proprietary compound library of small molecules and natural product new chemical entities (NCE), and targeted in-licensing opportunities to advance the development of promising new antibiotics in infectious diseases.

We believe our products have clinical and commercial potential that will capture a significant market opportunity in anti-infectives. The principal elements of our strategy are to:

Broaden our competitive strengths in working with infectious agents to develop superior therapeutic products for treatment of other underserved infectious diseases;

Partner with pharmaceutical and biotechnology companies, as well as academic institutions and governmental organizations, to accelerate product commercialization and to defray the cost of product development;

Complete proof-of-principle Phase 2 clinical development of our leading anti-infectives to create additional value and enhance our ability to partner; and

Monetize our non-core assets to provide additional funding for our anti-infectives development programs.